Navigation Links
Einstein researchers receive grants totaling $700,000 for innovative breast cancer research
Date:10/26/2007

(BRONX, NY) -- Three researchers at the Albert Einstein College of Medicine have been awarded grants from the Breast Cancer Research Foundation (BCRF). Drs. Thomas Rohan, Susan Horwitz and Rachel Hazan each received grants from the BCRF in its ongoing effort to support the advancement of breast cancer research. At the heart of the BCRFs generosity is its mission, which is to achieve prevention and a cure for breast cancer by providing critical funding for innovative clinical and genetic research at leading medical centers worldwide, while also increasing public awareness about good breast health.

Dr. Rohan, professor and chair of epidemiology and population health at Einstein, received $250,000 to carry out gene expression profilingusing so-called gene chipson women at risk of developing breast cancer. Using a technique that he and colleagues developed for extracting and storing RNA from breast tissue, Dr. Rohan will focus his efforts on women with benign breast disease (BDD), since women with this condition have an increased risk for breast cancer. For those BDD patients who eventually develop breast cancer, gene-expression profiles may help to predict clinical outcomes and identify those patients most likely to respond to therapy. Dr. Rohan and his colleagues have already established a multi-center cohort of more than 25,000 women who have undergone biopsies for BDD, and these breast tissue samples will be used in the study.

Dr. Horwitz, Falkenstein Professor of Cancer Research and co-chair of molecular pharmacology at Einstein, received $225,000 to study epigenetic changes (i.e., switching genes on and off in ways that dont involve changes in DNA sequence) in breast cancer cells that may help pinpoint why some breast tumors become drug-resistant. In particular, she will study whether epigenetic mechanisms cause cells to become resistant to Taxol, a drug she helped discover that has proven highly effective in treating breast cancer. Her work
'/>"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Einstein researchers identify new way that bacteria develop resistance to antibiotics
2. Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell
3. Feinstein researchers identify intelligence gene
4. Study by Einstein researchers could lead to a novel strategy for treating obesity
5. Einstein researchers take the pulse of a gene in living cells
6. Einstein researchers demonstrate a novel approach to treating AIDS
7. Einsteins tea leaves inspire new blood separation technique
8. Researchers discover way to make cells in the eye sensitive to light
9. Researchers find how protein allows insects to detect and respond to pheromones
10. Researchers Uncover Key Step In Manufacture of Memory Protein
11. NYU researchers simulate molecular biological clock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2
... A major step in commercializing the groundbreaking research ... University of Minnesota signed an exclusive, global license agreement ... worldwide attention in 2008 when her team announced that ... laboratory. The technology licensed to Miromatrix holds the ...
... Calif., Feb. 16, 2010 Butterfly experts have suspected for ... in explaining wing color diversity. Now, for the first time, ... at least in nine Heliconius species. ... ultraviolet colors also have UV-yellow pigment on their wings, reports ...
... coastal fog has decreased significantly over the past 100 years, ... according to a new study by University of California, Berkeley, ... a natural cycle of the result of human activity, but ... entire redwood ecosystem, the scientists say. , "Since 1901, the ...
Cached Biology News:U of Minnesota finalizes license agreement to form start-up company based on Doris Taylor research 2Butterfly vision, wing colors linked, UCI study finds 2Fog has declined in past century along California's redwood coast 2Fog has declined in past century along California's redwood coast 3Fog has declined in past century along California's redwood coast 4
(Date:12/22/2014)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, announced today the ... Calgary in conjunction with co-authors from Kyoto University and ... company,s ongoing clinical research using dermal sheath cup (DSC) ... The paper entitled " Hair Follicle Dermal Stem ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... to Host Conference Call at 12:30 p.m. Eastern Time, September 19, ... ... Sept. 19 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that ... obtained the,United States rights to SANCTURA(R) and SANCTURA(R) XR. In connection with,Allergan,s ...
... Corporation,(Nasdaq: CRGN ), a clinical-stage biopharmaceutical company ... M.D., has been appointed,President and Chief Executive Officer, ... remain with the Company through the end,of 2007, ... on CuraGen,s,Board of Directors until the Annual Stockholders ...
... for ... inflammatory bowel disease., OKLAHOMA CITY, Sept. 18 Altheus Therapeutics, ... trials,testing the efficacy of its therapy for the treatment of inflammatory ... by the,Oklahoma Seed Capital Fund and Oklahoma Equity Partners. About ...
Cached Biology Technology:Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer 2CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer 3CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer 4CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer 5Altheus Therapeutics Secures $3.6 Million in Venture Capital 2